# Visus Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/visus-therapeutics

- Industry: Biotechnology
- Headquarters: Seattle, US
- Website: www.visustx.com
- Total disclosed funding: $56M
- Latest round: Series A (Aug 10, 2021)
- Investors on record: 5

## About

Based in Washington, US, and founded in 2019 by Benjamin Bergo, Visus Therapeutics operates as a clinical-stage pharmaceutical company that develops presbyopia-correcting eye drop for patients' eye vision. The company has offices in Seattle, Washington, and Orange County, California. In August 2021, Visus Therapeutics raised USD 20 million in venture funding led by investors Life Sciences Partners, Sage Partners, and Johnson & Johnson Innovation. Further, in September 2022, Visus Therapeutics acquired ViewPoint Therapeutics from Asset Management Ventures, BVF Partners, Lagunita BioSciences, Mission Bay Capital, etc. The firm as of January 2024, is led by its Chairman, David Guyer, and CEO, Ben Bergo.

Visus Therapeutics, Inc. provides VTI-001 (BRIMOCHOL™) and VTI-003 that help billions of adults who suffer from presbyopia, known as loss of near vision. The lead clinical candidate is VTI-001 (BRIMOCHOL™), a daily eye drop designed to correct the loss of near vision associated with presbyopia. The company is specialized in Presbyopia, Ophthalmology, Optometry, and Eye Health.

## Funding rounds

- Series A, Aug 10, 2021, $20M — EQT Life Sciences, Johnson & Johnson Innovation, Sage Partners
- Series A, Mar 9, 2021, $36M — Johnson & Johnson Innovation, RTW Investments, Wille AG

## Investors

- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series A
- RTW Investments (https://capitalatlas.ai/funds/rtw-investments) — Series A
- Wille AG — Series A
- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series A
- Sage Partners (https://capitalatlas.ai/funds/sage-partners) — Series A